Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIN816 in Adult Patients at Risk for Acute Kidney Injury Following Cardiac Surgery
NCT05524051Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial of TIN-816 in acute kidney injury (AKI) (3 arms), sponsored by Novartis. Started Mar 2023; status: terminated.
02
Drugs
TIN-816
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05524051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05524051.